These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 30869167)

  • 21. Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of six randomized studies.
    Piña-Garza JE; Rosenfeld W; Saeki K; Villanueva V; Yoshinaga H; Patten A; Williams B; Malhotra M
    Epilepsy Behav; 2020 Mar; 104(Pt A):106876. PubMed ID: 31954998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy.
    Usui N; Akamatsu N; Nakasato N; Ohnishi A; Kaneko S; Hiramatsu H; Saeki K; Miyagishi H; Inoue Y
    Seizure; 2018 Nov; 62():26-32. PubMed ID: 30267941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial.
    French JA; Krauss GL; Wechsler RT; Wang XF; DiVentura B; Brandt C; Trinka E; O'Brien TJ; Laurenza A; Patten A; Bibbiani F
    Neurology; 2015 Sep; 85(11):950-7. PubMed ID: 26296511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic-clonic seizures.
    Fogarasi A; Flamini R; Milh M; Phillips S; Yoshitomi S; Patten A; Takase T; Laurenza A; Ngo LY
    Epilepsia; 2020 Jan; 61(1):125-137. PubMed ID: 31912493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjunctive perampanel and myoclonic and absence seizures: Post hoc analysis of data from study 332 in patients with idiopathic generalized epilepsy.
    Brandt C; Wechsler RT; O'Brien TJ; Patten A; Malhotra M; Ngo LY; Steinhoff BJ
    Seizure; 2020 Aug; 80():115-123. PubMed ID: 32563171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy, safety, and tolerability of adjunctive brivaracetam in adult Asian patients with uncontrolled focal-onset seizures: A phase III randomized, double-blind, placebo-controlled trial.
    Inoue Y; Tiamkao S; Zhou D; Cabral-Lim L; Lim KS; Lim SH; Tsai JJ; Moseley B; Wang L; Sun W; Hayakawa Y; Sasamoto H; Sano T; McClung C; Bass A
    Epilepsia Open; 2024 Jun; 9(3):1007-1020. PubMed ID: 38576178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perampanel as monotherapy or first adjunctive therapy in pediatric and adult patients with epilepsy: the first United States-based phase IV open-label ELEVATE study.
    Punia V; Klein P; Mihaylova T; Biton V; Samad O; Ngo LY; Kumar D; Malhotra M
    J Neurol; 2024 Jul; 271(7):4587-4598. PubMed ID: 38730096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term open-label perampanel: Generalized tonic-clonic seizures in idiopathic generalized epilepsy.
    French JA; Wechsler RT; Trinka E; Brandt C; O'Brien TJ; Patten A; Salah A; Malhotra M
    Epilepsia Open; 2022 Sep; 7(3):393-405. PubMed ID: 35445567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study.
    Singh K; Shah YD; Luciano D; Friedman D; Devinsky O; Kothare SV
    Epilepsy Behav; 2016 Aug; 61():41-45. PubMed ID: 27300147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: Pooled results from three Phase III studies.
    Moseley BD; Sperling MR; Asadi-Pooya AA; Diaz A; Elmouft S; Schiemann J; Whitesides J
    Epilepsy Res; 2016 Nov; 127():179-185. PubMed ID: 27608437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.
    French JA; Krauss GL; Steinhoff BJ; Squillacote D; Yang H; Kumar D; Laurenza A
    Epilepsia; 2013 Jan; 54(1):117-25. PubMed ID: 22905857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.
    Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Squillacote D; Yang H; Gee M; Zhu J; Laurenza A
    Epilepsia; 2013 Jan; 54(1):126-34. PubMed ID: 22905878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PERPRISE: A prospective non-interventional study of PERampanel as only adjunctive treatment in patients with PRImary or SEcondarily generalized tonic-clonic seizures: First interim analysis.
    Steinhoff BJ; Goldmann T; Kockelmann E; Winter Y;
    Epilepsia Open; 2024 Jun; 9(3):926-939. PubMed ID: 38017663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.
    Steinhoff BJ; Ben-Menachem E; Ryvlin P; Shorvon S; Kramer L; Satlin A; Squillacote D; Yang H; Zhu J; Laurenza A
    Epilepsia; 2013 Aug; 54(8):1481-9. PubMed ID: 23663001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307.
    Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Clément JF; Wang X; Bagul M; Gee M; Zhu J; Squillacote D
    Epilepsia; 2014 Jul; 55(7):1058-68. PubMed ID: 24867391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perampanel, an AMPA receptor antagonist: From clinical research to practice in clinical settings.
    Tsai JJ; Wu T; Leung H; Desudchit T; Tiamkao S; Lim KS; Dash A
    Acta Neurol Scand; 2018 Apr; 137(4):378-391. PubMed ID: 29214650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy.
    Ishikawa N; Tateishi Y; Tani H; Kobayashi Y; Kobayashi M
    Epilepsy Behav; 2019 May; 94():82-86. PubMed ID: 30897534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perampanel in the treatment of partial seizures: Time to onset and duration of most common adverse events from pooled Phase III and extension studies.
    Ko D; Yang H; Williams B; Xing D; Laurenza A
    Epilepsy Behav; 2015 Jul; 48():45-52. PubMed ID: 26057204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: The first real-world evaluation in Asian pediatric neurology clinics.
    Lin KL; Lin JJ; Chou ML; Hung PC; Hsieh MY; Chou IJ; Lim SN; Wu T; Wang HS
    Epilepsy Behav; 2018 Aug; 85():188-194. PubMed ID: 30032806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Perampanel in treatment of refractory partial epilepsy in adolescents and adults: results of international multicenter randomized, double-blind, placebo-controlled phase III studies].
    Belousova ED
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(8):32-8. PubMed ID: 25345628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.